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Abstract
Inflammatory bowel diseases (IBD) [Crohn’s disease (CD) and ulcerative colitis (UC)], are
chronic relapsing disorders of unknown etiology. The aim of this study was to determine demo-
graphic features, disease phenotypes, medical and surgical therapies in our IBD patients and
to identify which parameters are in association with the need of surgery and/or biologic therapy.
Data on demographic and clinical characteristics of the patients were analyzed from the IBD
registry of the 1st Department of Medicine, University of Szeged. The study period was
between January 2007 and March 2015. Data of 911 IBD patients (428 CD, 483 UC) were ana-
lyzed. The median lag time between onset of symptoms and diagnosis proved to be signifi-
cantly longer in UC than in CD (4.6 years vs. 2.1 years, p = 0.01). 40% of the patients received
biological therapy, 301 patients underwent surgery required more frequently for CD than UC.
Surgery was more common in CD patients with ileal location and penetrating behaviour. In UC,
more severe disease onset predicted to unfavourable disease course. Higher proportion of sur-
gery was shown in patient aged above 40 years in both CD and UC. Diagnostic delay of more
than 1 year and appendectomy predicted to unfavourable disease outcome of both CD and
UC. This analysis revealed that more than 1 year of diagnostic delay, disease activity at diagno-
sis in UC, CD, ileal location and penetrating behaviour are factors that may influence disease
outcome. Use of thiopurines seemed to be protective in UC.
Introduction
Inflammatory bowel diseases (IBD) [Crohn’s disease (CD) and ulcerative colitis (UC)], are
chronic relapsing disorders of the gastrointestinal tract without known etiology. The diseases
usually affect patients of younger age, and the risk of low quality of life due to chronic illness,
together with hospital admissions and increased need of surgical interventions is associated
with a higher risk of permanent work disability [1]. During the past decades, newer treatment
paradigms incorporate more common and earlier use of immunosuppressive and biological
therapies, which may lead to significant financial burdens of health care. The main role of
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these new therapeutic approaches is to favorably modify in the natural history of IBD, hope-
fully resulting in a decrease in complications and surgeries [2]. However, since the prevalence
of IBD is expected to increase, direct and indirect costs to both health care system and society
will also to be increased [3].
Descriptive epidemiologic studies and population-based cohort studies can provide valu-
able information about the burden of illness since identification of simple demographic and
clinical factors associated with disabling disease has high importance in the management of
IBD. However, only limited data are available from the Eastern Europe regarding to the rate of
more complicated disease course, use of biological therapy and number of surgeries.
The aim of this study was to determine demographic features, disease phenotypes, medical
and surgical therapies in our large IBD patients’ registry and to identify which parameters are
in association with the need of surgery and/or biologic therapy as surrogate markers of worse
disease course in CD and UC.
Patients and methods
Patients diagnosed with IBD have been prospectively participated in an IBD registry launched
at 1st Department of Medicine, University of Szeged in 2007. This is large, prospectively main-
tained database that captures demographic and clinical data including intestinal and extrain-
testinal symptoms, disease activity assessed by validated activity scores, previous and current
therapies, laboratory results and physiological parameters like blood pressure, heart rate, body
weight and height, results of physical investigations, findings of endoscopies and imaging
methods at every appointment of the patients. The registry includes both incident and preva-
lent cases. This database is suitable for the follow-up of patients since it records every visit of
the patient with all of the important and necessary information detailed above.
In this study clinical data and descriptive statistics of the IBD outpatients were extracted
and analyzed from the IBD registry of the 1st Department of Medicine, University of Szeged
between January 2007 and March 2015. Present age, age at diagnosis and at onset, smoking
habits, history of appendectomy, the presence of familial IBD, the presence of extraintestinal
manifestations, disease activities, number and type of surgeries, most important laboratory
parameters and therapies were registered at every appointment of each patient. The diagnosis
of CD and UC was based on the Lennard-Jones and later ECCO criteria [4]; disease phenotype
was defined by the Montreal Classification [5]. Disease activity was assessed by the Crohn’s
Disease Activity Index (CDAI) and the Mayo Scoring System in UC [6, 7]. On the basis of the
activity scores, patients were divided in inactive, mildly, moderately and severely active groups.
CRP was considered to be abnormal referring to active disease if being higher than 5 mg/l both
in UC and CD. In the majority of the patients, first attendance at the 1st Department of Medi-
cine, University of Szeged was the same as the time of the diagnosis. Worse disease course was
characterized by active disease with or without extraintestinal complications or perianal mani-
festations and the need of biological therapy and/or major surgery.
Differences in demographic and clinical characteristics, the presence of extraintestinal
manifestations, number of surgeries and different types of treatments between CD and UC
and predictors of outcomes in both diseases were analyzed statistically. Of therapies, cortico-
steroid, immunosuppressive and biological therapies were collected for statistical analysis.
Statistical analysis
Statistical analysis was carried out using STATA 9.0 software. The Pearson’s chi-square test,
Wilcoxon ranksum test, Kruskal-Wallis test and logrank test were performed to analyze data.
Median follow-up time with middle 50% interquartile range (IQR50%) were calculated. The
Disease outcome in IBD in a Hungarian center
PLOS ONE | https://doi.org/10.1371/journal.pone.0200824 July 30, 2018 2 / 8
16-2017-00006/efop-3-6-2-16-2017-00006). The
funders had no role in study design, data collection
and analysis, decision to publish or preparation of
the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
symptom free follow-up periods were compared using Kaplan-Meier product limit estimator.
A probability level of p<0.05 was considered to be significant.
Ethical approval
This study was approved by the Clinical Research Coordination Center University of Szeged
Faculty of Medicine Albert Szent-Gyo¨rgyi Health Center. Number of ethical licence: 2640
Results
Demographic data and clinical characteristics of patient population with
Crohn’s disease
428 CD patients diagnosed between January 2007 and April 2015 were included in the study.
Male/female proportion was 194/234. Mean age at onset of symptoms and at diagnosis was
26.6±11.3 and 27.9±11.4 years. At diagnosis, ileocolonic and colonic locations and non-stric-
turing, non-penetrating behaviour were the most common (35.3%, 34.6% and 44.4%) disease
phenotypes. Positive family history of IBD was reviewed in 8.8% of CD patients. Considering
extraintestinal manifestations, arthralgia and arthritis occurred in 54% of the patients. The
most common joints involved were knee, shoulder, hand, spine and hip.
Demographic data and clinical characteristics of ulcerative colitis patient
population
Data of 483 UC patients were analyzed in the study. Male/female proportion was 228/255.
Mean age at onset of symptoms and at diagnosis was 30.3±12.4 and 30.9±12.5 years. Proctitis
and left-sided colitis were the most frequent disease extents (34.2% and 34.6%). At the time of
the first appointment, registered disease activity was mild in 41.6%, moderate in 41.6%, and
severe in 12.2% of the UC patients. The remaining 4.6% of the patients was documented to
have inactive disease at the time of first appointment. Positive family history of IBD was regis-
tered in 11.3% of UC patients. Arthralgia and arthritis were present in 57.8% of the patients.
Proportions of biological therapy and/or surgery in CD
60.5% of the CD patients received thiopurine, 23.6% methylprednisolone, 45.6% biological
therapy and 28% combined thiopurine and biological therapy. In CD, use of thiopurine was
more common in patients with colonic and ileocolonic locations vs. ileal location (34.3% and
37.7% vs. 27.9%, p = 0.03). Need of biological therapy was not in association with any location
or behaviour of CD and the presence of extraintestinal manifestations.
Surgery was needed in 228 patients (number of surgical interventions (both abdominal and
perianal): 440). Bowel resection and perianal surgery was performed in 66% and 34% of the
cases. Surgery proved to be more common in patients with ileal location compared to colonic
and ileocolonic locations (p = 0.06) and with penetrating behaviour compared to non-strictur-
ing, non-penetrating and stricturing behaviour (p0.001). Higher proportion (58.2%) of sur-
gery was shown in patient aged above 40 years (p = 0.051). In CD, neither baseline CDAI or
CRP were associated with the need of biological therapy and/or surgery.
Proportions of biological therapy and/or surgery in UC
43.5% of UC patients were on thiopurine, 34.2% on methylprednisolone, 26.3% on biological
therapy and 14.8% on combined thiopurine and biological therapy during the whole period.
Use of thiopurines and biologicals did not show any association with disease extent.
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Colectomy was performed in 77 patients throughout the follow-up period. 51% of the
patients underwent laparoscopic surgery. One-, two,-and three-stage surgeries were performed
in 13.3%, 40% and 46.7% of the operated patients. Significantly higher proportion (75.3%) of
surgery was in patient aged above 40 years (p = 0.035). Disease extent did not show any associ-
ation with the need of surgery. Rate of surgery did not differ significantly in patients receiving
biologicals, however it was lower in patients treated with thiopurines (p = 0.045). Need of bio-
logical therapy and need of biological therapy and surgery together were more common in
patients with more severe disease activity determined by pMayo score and CRP level at the
first attendance (p0.001).
Comparison of the demographic and clinical parameters of CD and UC
patients
The median follow-up time of the patients was 3.6 years. Ratio of males/females did not differ
significantly among the two disease groups (p = 0.435). The median lag time between onset of
symptoms and diagnosis proved to be significantly longer in UC than in CD (4.6 years vs. 2.1
years, p = 0.01) (Table 1). However, after excluding cases where we were not able to perform a
complete follow-up of the medical records, no significant difference remained regarding the
median lag time between onset of symptoms and diagnosis.
Smoking and history of appendectomy were significantly more common in CD vs. UC
patients (p0.001 and p = 0.003). No difference was shown in the use of oral contraceptives
between the two patient groups. No association was found between either positive family his-
tory of IBD, or any of the accompanying extraintestinal manifestations and any of the disease
locations/extents or complicated disease behaviours in CD. Detailed demographic and clinical
characteristics of the enrolled patients are summarized in Table 2 (S1 Table).
Ratio of males/females did not differ regarding the use of thiopurines and/or biological
therapy. Rate of surgery proved to be significantly higher in CD vs. UC (p0.001). No rela-
tionship was found between smoking, appendectomy, positive family history of IBD and the
presence of extraintestinal manifestations and the need of surgery or biological therapy. Use of
oral contraceptives was protective on the need of surgery and biologicals in both diseases.
Rates of surgery and biological therapy together were significantly more common in patients
diagnosed more than 1 year after the onset of symptoms in CD and UC as well (p = 0.012 and
p = 0.002).
Discussion
The present study in which CD and UC patients were followed up for a median of 3.6 years
has resulted in several important findings. Considering the whole study population, median
Table 1. Median lag times between onset of symptoms and diagnosis in CD and UC.
Follow-up time (years)
Group No. of patients Median P25% P75% p-value
Total 911 3,6 0 9,6 <0,01
UC 483 4,6 0 10,3
CD 428 2,1 0 8,6
Non-zero follow-up time (years)
Total 589 7,9 3,9 12,2 0,86
UC 349 8 3,7 12,7
CD 240 7,7 4,2 11,9
https://doi.org/10.1371/journal.pone.0200824.t001
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lag time between onset of symptoms and diagnosis proved to be significantly longer in UC
than in CD. 33.5% of the patients underwent surgery required more frequently for CD than
UC. Biological therapy was given for 40%, immunomodulators for 53% of the patients. More
patients needed surgery or biological therapy if they were diagnosed more than 1 year after the
onset of symptoms. Surgery was more common in CD patients with ileal location and pene-
trating behaviour but did not show any association with disease extent of UC. Rate of surgery
was lower in patients treated with thiopurines in UC. Higher proportion of surgery was shown
in patient aged above 40 years in both CD and UC. Use of oral contraceptives was protective
on surgery and the need of biological therapy and age above 40 years also proved to be protec-
tive on the need of biologicals in both diseases.
The overall prevalence and incidence of both CD and UC is increasing worldwide. Previous
data suggested that approximately 2–14% of patients with CD and UC have a family history of
IBD [8]. Our data revealed a bit higher proportion of IBD patients having positive family his-
tory of the disease. Smoking is one of the most consistently examined risk factors in IBD being
associated with a more aggressive disease course in CD [9–11]. In our cohort, smoking did not
prove to be a predictor of unfavourable disease outcome despite the proportion of current
smokers was significantly higher in CD vs. UC. Appendectomy also shows different effects
in CD and UC [12–14], however, our results could not confirm that appendectomy was
Table 2. Demographic and clinical characteristics of the enrolled patients.
CD patients (n = 428) UC patients (n = 483)
Mean age at the present (years) 41.2±13.8 (SD:0.67) 47.4±15.2 (SD:0.69)
Mean age at diagnosis (years) 27.9±11.4 30.9±12.5
Mean age at onset of symptoms (years) 26.6±11.3 (SD: 0.56) 30.3±12.4 (SD:0.58)
Male/female ratio 194/234 228/255
Smoking habits (n, %)
- Ex smoker 109/385 (28.3) 148/448 (33)
- Current smoker 107/385 (27.8) 37/448 (8.2)
- Never smoked 169/385 (43.9) 263/448 (58.7)
Appendectomy (n, %) 76/378 (20.1) 26/448 (5.8)
Use of oral contraceptives (n, %) 119/372 (32) 146/437 (33.4)
Location/extent (n, %)
- Ileal 110 (25.7) NA
- Colonic 156 (34.6) NA
- Ileocolonic 151 (35.3) NA
- Isolated upper GI 11 (2.6) NA
- Proctitis NA 165 (34.2)
- Left-sided colitis NA 167 (34.6)
- Extensive colitis NA 151 (31.3)
Behaviour (n, %)
-Non-stricturing, non-penetrating 190 (44.4) NA
-Stricturing 101 (23.6) NA
-Penetrating 136 (31.8) NA
-Perianal manifestation 63 (14.7) NA
Extraintestinal manifestations (n, %)
- Eye 27 (6.3) 18 (3.7)
- Skin 55 (12.9) 69 (14.3)
- Joint 231 (54) 279 (57.8)
https://doi.org/10.1371/journal.pone.0200824.t002
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associated with the need of biological therapy and/or surgery in CD and could not reveal pro-
tective effect in UC.
According to the results of the IBSEN cohort, 45% of the CD patients were diagnosed with
colonic location and 60.5% with non-stricturing, non-penetrating behaviour at the time of
diagnosis [15]. In UC, the initial extent of the disease was proctitis in 32%, proctosigmoiditis
and left-sided colitis in 35% and extensive colitis in 33% [16]. In our study, the most common
locations and behaviour of CD and the distributions of the different extents of UC were the
nearly the same. An Australian study of Niewiadomski O et al. established a population-based
registry to assess disease course in IBD [17]. Immunomodulators were prescribed in 57% of
CD patients, and 19% with UC, steroids were used in 74% of CD and 63% of UC patients.
Only 13% of CD patients were started on biological therapy. In our study, more than half of
the patients received immunomodulators and more than one third of the patients received bio-
logical therapy during the whole follow-up period. Use of thiopurine was more common in
CD patients with colonic and ileocolonic locations. Use of methylprednisolone seems to be
lower in our cohort, although it also varies in the IBSEN studies-43% of the UC patients and
72% of CD patients had taken systemic glucocorticoids during the 5-year follow-up [15, 16].
In the Australian study, among CD patients, age< 25 years at diagnosis, ileocolonic and peria-
nal disease were risk factors for biological therapy [17]. In our cohort, no relationship was
found between location and behaviour of CD and disease extent of UC and the use of biologi-
cal therapy, however need of biologicals was more common in patients below the age of 40
years and in UC patients with more severe initial disease activity.
In the IBSEN cohort, 28% of the CD patients underwent surgery with intestinal resection
[15]. Intestinal resection rates were 26% at 5 years in the study of Niewiadomski et al. Risk fac-
tors of surgery included penetrating and stricturing disease and ileal involvement [17]. Colect-
omy rate in UC was 13% at 5 years with high CRP at diagnosis associated with colectomy [17].
According to the data of UC patients from IBSEN studies, overall colectomy rate proved to be
7.5% and 9.8% during the 5 and 10-year follow up periods [16, 18]. Initial presentation includ-
ing extensive colitis, elevated ESR, anaemia and fever was significantly associated with an
increased risk and age50 years with a reduced risk of subsequent colectomy. In our cohort
we found lower rate of surgery in patients treated with thiopurines. In CD, ileal location and
penetrating behaviour, in UC, more severe initial disease activity (assessed by high CRP and
pMayo score) and in both diseases age above 40 years at diagnosis related to surgery [16].
The systematic review and meta-analysis of Dias et al. highlights that delay in diagnosis is a
crucial factor for unfavourable disease outcome in IBD, since due to delays in diagnosis, disease
activity and bowel damage start to worsen in the lack of appropriate therapy [19]. A delay in
confirming the diagnosis of IBD is associated with increased need for surgery, poorer treatment
outcomes, reduced quality of life, and extent of disease [20, 21]. A French study revealed that diag-
nostic delay more than 12 months is associated with the presence of disease complications, suggest-
ing that a delay in diagnosis beyond 12 months may result in missing the therapeutic window to
intervene before disease complications occur [22]. Our results also suggest that more than 1 year
diagnostic delay may relate to higher risk of surgery and need of biological therapy in CD and UC.
The major strength of the present study is the prospective inclusion and follow-up of inci-
dent IBD patients diagnosed in one of the largest IBD center of Hungary. The relatively high
number of patients represents correctly the Hungarian IBD population. The patients are unse-
lected and represent the whole spectrum of disease severity. Additionally, this study character-
ized a long follow-up period of both CU and CD patients However, as a limitation, there were
cases in which we were not able to perform a complete follow-up of the medical records. After
excluding these data from statistical analysis, no significant difference remained regarding the
median lag time between onset of symptoms and diagnosis.
Disease outcome in IBD in a Hungarian center
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In this study we used objective measures, surgery and need of biological therapy as surro-
gate markers of worse disease course. Our follow-up study on almost 1000 IBD patients
revealed that at diagnosis of IBD in a referral center, factors predictive of surgery were age
below 40, although age above 40 years proved to be protective on the need of biologicals in
both diseases as well as use of oral contraceptives. However, more than 1 year of diagnostic
delay, disease activity at diagnosis in UC, CD, ileal location and penetrating behaviour seems
also to be important factors that may influence disease outcome. Use of thiopurines seemed to
be protective in UC.
Improvement of treatment strategies to minimize structural bowel damage and complica-
tions of disease has an increasing role in IBD. Hopefully the new trends in IBD management
and the optimization of therapeutic options, combined with new drugs, will make possible to
change the course of disease and provide better therapy and quality of life for patients suffering
from IBD.
Supporting information
S1 Table. Demographic and clinical characteristics of the enrolled patients. There is no
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